Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
about
Emerging use of everolimus in the treatment of neuroendocrine tumors.Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors.Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea.
P2860
Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Efficacy and safety of everoli ...... ncreatic neuroendocrine tumor.
@en
type
label
Efficacy and safety of everoli ...... ncreatic neuroendocrine tumor.
@en
prefLabel
Efficacy and safety of everoli ...... ncreatic neuroendocrine tumor.
@en
P2093
P2860
P1476
Efficacy and safety of everoli ...... ncreatic neuroendocrine tumor.
@en
P2093
Baek-Yeol Ryoo
Changhoon Yoo
Heejung Chae
Heung-Moon Chang
Hyungwoo Cho
Kyu-Pyo Kim
Min Jeong Song
Min-Hee Ryu
Seung-Mo Hong
Song Cheol Kim
P2860
P2888
P304
P356
10.1007/S00280-016-3215-3
P577
2016-12-10T00:00:00Z
P6179
1002115230